Pharma Hubs: The Access Infrastructure Keeping Patients on Specialty Drugs

The Middlemen Saving Patients from the Maze of Specialty Drug Access

A patient newly diagnosed with multiple sclerosis receives a prescription for a disease-modifying therapy that costs $80,000 a year. Their insurance requires prior authorization. A second insurer may need a step therapy protocol completed first. A co-pay assistance program exists but requires enrollment documentation the patient has never heard of. The specialty pharmacy needs a referral. Each of these steps is a potential dropout point — a place where a patient who needs a medication simply stops pursuing it because the process has become too complex to navigate alone.Pharma hubs exist to prevent that dropout. They are the operational infrastructure that specialty pharmaceutical manufacturers build — or contract out — to move patients from prescription to dispensing as efficiently as possible, and a structured account of how this sector is developing is available in this specialty pharma patient access and hub services industry overview. The market is less visible than the drugs it supports, but it is arguably as important to patient outcomes.

What a Hub Actually Does

The term "pharma hub" is used loosely, which creates some confusion. At its core, a hub service acts as a centralized coordination point for everything that happens between a physician writing a prescription and a patient receiving a specialty medication. Prior authorization support, benefits verification, co-pay card enrollment, patient assistance program qualification, specialty pharmacy routing, adherence monitoring — all of it can flow through the hub.

Manufacturers of high-cost specialty drugs have strong commercial incentives to build this infrastructure. A patient who gives up during the access process is not just a lost sale; in therapeutic areas where early treatment initiation correlates with better outcomes, delayed access is a clinical problem. Biogen's hub for its MS portfolio, Genentech's OneSource program, and AbbVie's myAbbVie Assist are examples of manufacturer-sponsored programs that have become models for how branded hub services operate.

The Prior Authorization Problem Is the Hub Market's Engine

Prior authorization — the requirement that insurers approve a prescription before dispensing — is the single largest friction point in specialty drug access. A 2022 survey by the American Medical Association found that 94% of physicians reported care delays due to prior authorization requirements, and 33% said a patient experienced a serious adverse event as a result of those delays. These are not abstract bureaucratic inconveniences. They are clinical failures embedded in the reimbursement architecture.

Hub services have become experts in prior authorization management because the manufacturers who fund them have the most sophisticated knowledge of what documentation a payer requires for each drug they make. A hub team that processes hundreds of prior authorizations per week for a single product develops an operational efficiency that a physician's office staff — managing authorizations across dozens of drugs and dozens of payers — structurally cannot match.

Where Third-Party Vendors Enter the Picture

Not every pharmaceutical company builds its own hub infrastructure. A robust third-party market has developed around hub services, with companies like AssistRx, Lash Group (part of AmerisourceBergen), and ConnectiveRx competing to provide outsourced hub capabilities across multiple manufacturer clients.

The pharma hub and patient access support service market has been evolving toward more technology-driven offerings. Electronic prior authorization integrations with EHR systems, real-time benefits verification tools, and patient engagement platforms that send automated reminders and track adherence are all being incorporated into hub service offerings. The competitive differentiation has shifted from "we have people who know how to do this" to "our technology reduces time-to-therapy by a measurable number of days."

The Tension Nobody Discusses Openly

Hub services are funded by pharmaceutical manufacturers, which creates a structural tension worth acknowledging. The hub's interest is in facilitating patient access to one specific drug — the manufacturer's product — rather than helping patients navigate the full range of therapeutic options. Physicians and patients who rely on hub services for access navigation are, in a sense, receiving support from a commercially interested party.

This isn't necessarily corrupt — the drug may well be the right choice — but it is a dynamic that influences how hub services are designed and what information they prioritize. As payers and providers develop more sophisticated views of hub services, the question of where manufacturer-funded access support ends and biased commercial promotion begins will only become more pressing.